Blood plasma serves as key raw material in blood product industry. In August
2011, the shut-down of 16 plasma collection stations in Guizhou province,
China resulted in a YoY decline of 15% in plasma volume and further
intensified the tight supply of raw material plasma. But when it comes to the
lot release volume, the blood product output in China grew as high as 15.4%
YoY in 2011, and the market size rose 22% YoY to around RMB11.6 billion.
Additionally, in consideration of 12th Five-Year Plan for Doubling Blood
Product Supply proposed by the Minister of the Ministry of Health at the end
of 2011, the issuance of Notice of the Ministry of Health on Management of
Plasma Collection Stations in early 2012, and the domestic market demand &
supply, the blood product market size in China is expected to maintain a high
growth rate of over 20% in the five years to come.
However, the low degree of industry concentration, the companies' weak R&D
capabilities, short supply of raw material plasma and low plasma utilization
rate affect the development of Chinese blood product industry to some extent.
The blood products released in overseas market divide into around 40
varieties, and the international blood product giants can extract about 15
varieties of blood products from plasma, while among Chinese companies,
Beijing Tiantan Biological Products Co., Ltd. can produce at most 11 varieties
from plasma. Moreover, Chinese blood product market is principally
concentrated on human albumin and human immunoglobulin (pH4) for intravenous
injection which pose low requirements on technologies. In 2011, the lot
release volume of the two products made up 53.4% and 16.8% of the total
release volume respectively.
Product Structure of Blood Products in China (by Lot Release Volume), 2009-2011
Source: National Institute for Food and Drug Control;
7 Regional Institutes for Drug Control;
ResearchIn China: “China Blood Product Industry Report, 2011-2012”
Blood coagulation factor and thrombin products feature the largest demand gap
in China, but there are less domestic supply and fewer producers. In 2011, the
manufacturers of Human Coagulation Factor VIII in China just include Shanghai
RAAS Blood Products, Green Cross China and Hualan Biological Engineering Inc.,
with lot release volume adding up to 350,000 bottles, and the producers of
Human Prothrombin Complex are Hualan Biological Engineering Inc., Shanghai
RAAS Blood Products and Shanghai Xinxing Medicine, with lot release volume
totaling 200,000 bottles. Essentially, subsidiaries under China National
Biotech Group and other Groups that possess production capacity and obtain
governmental approvals in Coagulation Factor VIII and IX do not conduct
production in recent years. With the intensifying contradiction between supply
and demand, the government may launch intervention measures to enable the
enterprises with the approval to restart the manufacturing of these products
to raise overall supply of products of this sort.
Although taking such factors like home market demand into account, China has
allowed the import of some blood products, but the imports are confined to
human albumin and recombinant coagulation factor. Moreover, blood product
manufacturing is a sector with no allowance for foreign capital. The imported
human albumin almost makes up 50% market share, and the proportion reached
43.3% in 2011.
Following the tougher conflict between supply & demand and the loosening of
policies in China, foreign brands quicken their pace of tapping into Chinese
market. In May 2012, SFDA approved the release of Baxter's ADVATE (Recombinant
Human Coagulation Factor VIII for injection) in China which was another
foreign brand of coagulation factor after the imported Bayer's Recombinant
Coagulation Factor VIII in 2007. Moreover, Pfizer is applying for quick
approval program for its Recombinant Coagulation Factor IX (obtained from
Wyeth).
The report resolves around the followings:
The plasma volume, distribution of plasma stations, market size and supply
& demand of Chinese blood product industry;
Competition pattern, policy climate and import & export of Chinese blood
product industry;
Market supply & demand and competitive landscape of 8 blood products such
as human albumin, human immunoglobulin (pH4) for intravenous injection and
coagulation factor, etc.
Status quo, operation, plasma collection station and product lot release
volume of 9 Chinese blood product manufacturers
STUDY GOAL AND OBJECTIVES
This report provides the industry executives with strategically
significantcompetitor information, analysis, insight and projection on
thecompetitive pattern and key companies in the industry, crucial to
thedevelopment and implementation of effective business, marketing andR&D
programs.
REPORT OBJECTIVES
To Eestablish a comprehensive, factual, annually updated and
cost-effective information base on market size, competition patterns, market
segments, goals and strategies of the leading players in the market, reviews
and forecasts.
To assist potential market entrants in evaluating prospective acquisition
and joint venture candidates.
To complement the organizations' internal competitor information gathering
efforts with strategic analysis, data interpretation and insight.
To suggest for concerned investors in line with the current development of
this industry as well as the development tendency.
To help company to succeed in a competitive market, and
METHODOLOGY
Both primary and secondary research methodologies were used in preparing this
study. Initially, a comprehensive and exhaustive search of the literature on
this industry was conducted. These sources included related books and
journals, trade literature, marketing literature, other product/promotional
literature, annual reports, security analyst reports, and other publications.
Subsequently, telephone interviews or email correspondence was conducted with
marketing executives etc. Other sources included related magazines, academics,
and consulting companies.
INFORMATION SOURCES
The primary information sources include National Institutes for Food and Drug
Control, local Institutes for Drug Control and listed companies etc .
Table of Contents
Table of Contents
1. Profile of Blood Products
1.1. Definition
1.2. Classification
1.3. Recombinant Blood Products
1.4. Industry Chain
1.5. Features
2. Overview of China Blood Products Industry
2.1. Market Size
2.2. Development Status
2.3. Market Supply & Demand
2.3.1. Supply
2.3.2. Demand
2.4. Market Competition
2.5. Operating Environment
2.5.1. International Market
2.5.2. Policies
2.5.3. Domestic Biopharmaceutical Market
2.6. Import & Export
3. Blood Product Market Segments in China
3.1. Human Albumin
3.1.1. Supply & Demand
3.1.2. Competition Pattern
3.1.3. Prospects
3.2. Human Immunoglobulin (pH4) for Intravenous Injection
4.7. CNBG Shanghai Institute of Biological Products
4.7.1. Profile
4.7.2. Blood Products
4.8. Shanxi Kangbao Biological Product Co., Ltd.
4.8.1. Profile
4.8.2. Blood Products
4.9. Green Cross
4.9.1. Profile
4.9.2. Blood Products
Selected Charts
Basic Components of Blood
Classification and Effects of Blood Products
Comparison between Gene Recombinant Blood Products and Traditional Blood
Products
Categories and Comparison of Recombinant Blood Products in China and
Worldwide
Blood Product Industry Chain
Blood Product Market Scale in China, 2003-2015E
Lot Release Volume of Blood Products (by Product) in China, 2007-2011
Product Structure of Blood Products in China (by Lot Release Volume),
2009-2011
Annual Plasma Volume in China, 2002-2011
Geographical Distribution of Plasma Collection Station Resources in China,
by the End of 2011
Medical Insurance Coverage in Mainstream Blood Products in China
Comparison of Per Capita Usage of Blood Products between China and
Developed Countries
Distribution of Plasma Collection Stations, Plasma Volume and Blood
Products Revenue of Chinese Major Blood Product Manufacturers, 2011
Comparison among Blood Product Manufacturing Enterprises in China by
Product Line
Blood Products in Overseas Countries
On-going Clinical Trial of New Indications Overseas
Global Blood Products Manufacturers
Major Policies Concerning Blood Products in China
Sales Value and Total Profit of Biological & Biochemical Product Industry
in China, 2008-2011
Ratio of Domestic and Imported Human Albumin in China (by Lot Release
Volume), 2007-2010
Market Share of Major Manufacturers of Human Albumin in China (by Lot
Release Volume), 2007-2011
Comparison between China and USA by Consumption of Human Immunoglobulin
(pH4) for Intravenous Injection, 2010
Lot Release Volume and Its Growth Rate of Human Immunoglobulin (pH4) for
Intravenous Injection in China, 2007-2010
Prices of Human Immunoglobulin (pH4) for Intravenous Injection in China
and Other Countries
Market Share of Major Manufacturers of Human Immunoglobulin (pH4) for
Intravenous Injection in China (by Lot Release Volume), 2007-2011
Lot Release Volume and Its Growth Rate of Coagulation Factor VIII in
China, 2008-2011
Market Share of Major Manufacturers of Coagulation Factor VIII in China
(by Lot Release Volume), 2008-2011
Comparison between Human-derived Coagulation Factor VIII and Recombinant
Coagulation Factor VIII
Lot Release Volume and Its Growth Rate of Hepatitis B Immunoglobulin in
China, 2008-2011
Market Share of Major Manufacturers of Hepatitis B Immunoglobulin in China
(by Lot Release Volume), 2008-2011
Lot Release Volume and Its Growth Rate of Human Immunoglobulin in China,
2008-2011
Market Share of Major Manufacturers of Human Immunoglobulin in China (by
Lot Release Volume), 2008-2011
Lot Release Volume and Its Growth Rate of Human Prothrombin Complex in
China, 2008-2011
Market Share of Manufacturers of Human Prothrombin Complex in China (by
Release Volume), 2008-2011
Lot Release Volume and Its Growth Rate of Tetanus Immunoglobulin in China,
2008-2011
Market Share of Major Manufacturers of Tetanus Immunoglobulin in China (by
Release Volume), 2008-2011
Lot Release Volume and Its Growth Rate of Human Rabies Immunoglobulin in
China, 2008-2011
Market Share of Major Manufacturers of Human Rabies Immunoglobulin in
China (by Release Volume), 2008-2011
Revenue and Total Profit of Hualan Biological, 2007-2012
Revenue Breakdown of Hualan Biological by Industry, 2007-2011
Revenue Structure of Hualan Biological by Industry, 2007-2011
Revenue Breakdown of Hualan Biological by Product, 2007-2011
Revenue Structure of Hualan Biological by Product, 2007-2011
Revenue Breakdown of Hualan Biological by Region, 2007-2011
Revenue Structure of Hualan Biological by Region, 2007-2011
Gross Margin of Hualan Biological by Industry, 2007-2011
Gross Margin of Hualan Biological by Product, 2007-2011
Hualan Biological's Revenue from Top 5 Clients and % of Total Revenue,
2007-2011
Hualan Biological's Procurement from Top 5 Suppliers and % of Total
Procurement, 2007-2011
R&D Costs and % of Total Revenue of Hualan Biological, 2007-2011
Distribution of Plasma Collection Stations of Hualan Biological, 2011
Lot Release Volume of Blood Products of Hualan Biological, 2008-2011
Proportion of Blood Products Release Volume of Hualan Biological, 2008-2011
Revenue and Gross Margin of Blood Products of Hualan Biological, 2007-2011
Revenue and Gross Margin of Blood Products of Hualan Biological (by
Product), 2007-2011
Distribution of Plasma Collection Stations of Shanghai RAAS Blood Products
Co., Ltd, by the End of 2011
Revenue and Profit of Shanghai RAAS, 2007-2012
Lot Release Volume of Blood Products of Shanghai RAAS Blood Products Co.,
Ltd, 2007-2011
Proportion of Blood Products Release Volume of Shanghai RAAS, 2007-2011
Revenue Breakdown of Shanghai RAAS by Product, 2007-2011
Revenue Structure of Shanghai RAAS by Product, 2007-2011
Revenue Breakdown of Shanghai RAAS by Region, 2007-2011
Revenue Structure of Shanghai RAAS by Region, 2007-2011
Gross Margin of Shanghai RAAS by Product, 2007-2011
Shanghai RAAS's Revenue from Top 5 Clients and % of Total Revenue,
2007-2011
Name List and Revenue Contribution of Shanghai RAAS's Top 5 Clients, 2011
Shanghai RAAS's Procurement from Top 5 Suppliers and % of Total
Procurement, 2007-2011
R&D Costs and % of Total Revenue of Shanghai RAAS, 2007-2011
Revenue and Net Income of Tiantan Biological's Major Joint-stock
Companies, 2011
Revenue and Total Profit of Beijing Tiantan Biological, 2007-2012
Revenue Breakdown of Beijing Tiantan Biological by Industry, 2007-2011
Revenue Breakdown of Beijing Tiantan Biological by Region, 2007-2011
Gross Margin of Beijing Tiantan Biological by Industry, 2007-2011
Beijing Tiantan Biological's Procurement from Top 5 Suppliers and % of
Total Procurement,
2007-2011
Beijing Tiantan Biological's Revenue from Top 5 Clients and % of Total
Revenue, 2007-2011
Name List and Revenue Contribution of Top 5 Clients of Beijing Tiantan
Biological's Top 5 Clients, 2011
Distribution of Plasma Collection Stations of Beijing Tiantan Biological,
by the End of 2011
Revenue and Gross Margin of Blood Products of Beijing Tiantan Biological,
2007-2011
Lot Release Volume of Blood Products of Chengdu Rongsheng, 2007-2011
Equity Structure of China Biologic Product Inc.
Revenue and Operating Income of China Biologic Products Inc., 2007-2011
Revenue Structure of China Biologic Products Inc. by Product, 2008-2011
Plasma Collection Costs of China Biologic Products Inc., 2008-2011
China Biologic Products Inc.'s Revenue from Top 5 Clients and % of Total
Revenue, 2008-2011
Name List and Revenue Contribution of China Biologic Products Inc.'s Top 5
Clients, 2011
Name List and Procurement Contribution of China Biologic Products Inc.'s
Top 10 Suppliers, 2011
Lot Release Volume of Blood Products of Shandong Taibang, 2007-2011
Lot Release Volume of Blood Products of Guiyang Qianfeng, 2007-2011
Lot Release Volume of Blood Products of Xi'an Hui Tian, 2007-2011
Plasma Inventory, Plasma Collection Amount and Plasma Volume of Boya
Biopharmaceutical, 2009-2011
Distribution and Collection Amount of Plasma Collection Stations of Boya
Biopharmaceutical, 2009-2011
Revenue and Profit of Boya Biopharmaceutical, 2009-2012
Revenue Breakdown of Boya Biopharmaceutical by Product, 2009-2011
Revenue Structure of Boya Biopharmaceutical by Product, 2009-2011
Lot Release Volume of Blood Products of Boya Biopharmaceutical, 2007-2011
Revenue Breakdown of Boya Biopharmaceutical by Region, 2009-2011
Revenue Structure of Boya Biopharmaceutical by Region, 2009-2011
Gross Margin of Boya Biopharmaceutical by Product, 2009-2011
Boya Biopharmaceutical's Revenue from Top 5 Clients and % of Total
Revenue, 2009-2011
Name List and Revenue Contribution of Boya Biopharmaceutical's Top 5
Clients, 2011
Boya Biopharmaceutical's Procurement from Top 5 Suppliers and % of Total
Procurement, 2009-2011
Name List and Procurement Contribution of Boya Biopharmaceutical's Top 5
Suppliers, 2011
Output & Sales Volume and Inventory of Boya Biopharmaceutical by Product,
2009-2011
Prices of Boya Biopharmaceutical by Product, 2009-2011
R&D Costs and % of Total Revenue of Boya Biopharmaceutical, 2009-2011
Blood Product R&D Projects and Progress of Boya Biopharmaceutical, by the
End of 2011
Distribution of Plasma Collection Stations of Yuanda Shuyang, by the End
of 2011
Lot Release Volume of Blood Products of Yuanda Shuyang, 2007-2011
Lot Release Volume of Blood Products of CNBG Shanghai Institute of
Biological Products, 2007-2011
Distribution of Plasma Collection Stations of CNBG Shanghai Institute of
Biological Products, by the End of 2011
Distribution of Plasma Collection Stations of Shanxi Kangbao, by the End
of 2011
Lot Release Volume of Blood Products of Shanxi Kangbao, 2007-2011
Distribution of Plasma Collection Stations of Green Cross, by the End of
2011
Lot Release Volume of Blood Products of Green Cross, 2007-2011
China Blood Products Industry Report, 2011-2012 published by ResearchInChina in June 29, 2012. This report consists of 112 Pages and the price starts from US $ 2300.
The contents of this page may be different from the latest version. Please contact us for details.
